{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:48:42Z","timestamp":1782211722324,"version":"3.54.5"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12325-026-03536-0","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T08:19:30Z","timestamp":1776673170000},"page":"2977-2995","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Patterns and Perceptions of Treatment Options in Japanese Pediatric and Adolescent Patients with Atopic Dermatitis"],"prefix":"10.1007","volume":"43","author":[{"given":"Akio","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2624-7879","authenticated-orcid":false,"given":"Yumi","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Danjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoe","family":"Torisu-Itakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simran","family":"Marwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Piercy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atushi","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"issue":"10","key":"3536_CR1","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1111\/1346-8138.16527","volume":"49","author":"H Saeki","year":"2022","unstructured":"Saeki H, Ohya Y, Furuta J, et al. English version of clinical practice guidelines for the management of atopic dermatitis 2021. J Dermatol. 2022;49(10):e315\u201375.","journal-title":"J Dermatol"},{"issue":"2","key":"3536_CR2","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43\u201356.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"3536_CR3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/cea.13784","volume":"51","author":"S de Lusignan","year":"2021","unstructured":"de Lusignan S, Alexander H, Broderick C, et al. The epidemiology of eczema in children and adults in England: a population-based study using primary care data. Clin Exp Allergy. 2021;51(3):471\u201382.","journal-title":"Clin Exp Allergy"},{"issue":"8","key":"3536_CR4","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1111\/all.15721","volume":"78","author":"L Maintz","year":"2023","unstructured":"Maintz L, Schmitz M-T, Herrmann N, et al. Atopic dermatitis: correlation of distinct risk factors with age of onset in adulthood compared to childhood. Allergy. 2023;78(8):2181\u2013201.","journal-title":"Allergy"},{"issue":"9","key":"3536_CR5","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/1346-8138.12220","volume":"40","author":"C Yano","year":"2013","unstructured":"Yano C, Saeki H, Ishiji T, et al. Impact of disease severity on work productivity and activity impairment in Japanese patients with atopic dermatitis. J Dermatol. 2013;40(9):736\u20139.","journal-title":"J Dermatol"},{"key":"3536_CR6","unstructured":"Schwartz RA. Medscape: Pediatric Atopic Dermatitis\u00a0Clinical Presentation 2023. https:\/\/emedicine.medscape.com\/article\/911574-clinical. Accessed 21 Dec 2023."},{"issue":"5","key":"3536_CR7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/pde.15399","volume":"40","author":"Y Ohya","year":"2023","unstructured":"Ohya Y, Saeki H, Nawata H, et al. The disease burden of pediatric patients with atopic dermatitis in Japan. Pediatr Dermatol. 2023;40(5):851\u20136.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"3536_CR8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.23736\/S2784-8671.21.07072-9","volume":"157","author":"N Milanesi","year":"2022","unstructured":"Milanesi N, Gola M, Cartocci A, et al. Effect of dupilumab on sleep disturbances in adult patients with severe atopic dermatitis. Ital J Dermatol Venereol. 2022;157(2):142\u20135.","journal-title":"Ital J Dermatol Venereol"},{"issue":"4","key":"3536_CR9","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/bjd.18296","volume":"182","author":"L Andersen","year":"2020","unstructured":"Andersen L, Nyeland ME, Nyberg F. Increasing severity of atopic dermatitis is associated with a negative impact on work productivity among adults with atopic dermatitis in France, Germany, the U.K. and the U.S.A. Br J Dermatol. 2020;182(4):1007\u201316.","journal-title":"Br J Dermatol"},{"issue":"1","key":"3536_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02948-x","volume":"21","author":"AD Henderson","year":"2023","unstructured":"Henderson AD, Adesanya E, Mulick A, et al. Common mental health disorders in adults with inflammatory skin conditions: nationwide population-based matched cohort studies in the UK. BMC Med. 2023;21(1):285.","journal-title":"BMC Med"},{"key":"3536_CR11","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.5285","volume":"103","author":"L Misery","year":"2023","unstructured":"Misery L, Seneschal J, Corgibet F, et al. Impact of atopic dermatitis on patients and their partners. Acta Derm Venereol. 2023;103:adv5285.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"3536_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/DER.0000000000000582","volume":"31","author":"K Capozza","year":"2020","unstructured":"Capozza K, Gadd H, Kelley K, Russell S, Shi V, Schwartz A. Insights from caregivers on the impact of pediatric atopic dermatitis on families: \u201cI\u2019m tired, overwhelmed, and feel like I\u2019m failing as a mother.\u201d Dermatitis. 2020;31(3):223\u20137.","journal-title":"Dermatitis"},{"issue":"4","key":"3536_CR13","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jaad.2017.06.042","volume":"77","author":"EL Simpson","year":"2017","unstructured":"Simpson EL, Bruin-Weller M, Flohr C, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017;77(4):623\u201333.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"3536_CR14","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.alit.2022.06.009","volume":"71","author":"H Saeki","year":"2022","unstructured":"Saeki H, Ohya Y, Furuta J, et al. Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021. Allergol Int. 2022;71(4):448\u201358.","journal-title":"Allergol Int"},{"issue":"6","key":"3536_CR15","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40257-017-0284-y","volume":"18","author":"W Wei","year":"2017","unstructured":"Wei W, Anderson P, Gadkari A, et al. Discordance between physician- and patient-reported disease severity in adults with atopic dermatitis: a US cross-sectional survey. Am J Clin Dermatol. 2017;18(6):825\u201335.","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"3536_CR16","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","volume":"140","author":"CR Charman","year":"2004","unstructured":"Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients\u2019 perspective. Arch Dermatol. 2004;140(12):1513\u20139.","journal-title":"Arch Dermatol"},{"issue":"6","key":"3536_CR17","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/j.1365-2133.1995.tb16953.x","volume":"132","author":"MS Lewis-Jones","year":"1995","unstructured":"Lewis-Jones MS, Finlay AY. The Children\u2019s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942\u20139.","journal-title":"Br J Dermatol"},{"key":"3536_CR18","doi-asserted-by":"crossref","unstructured":"Saeki H, Ohya Y, Arakawa H, et al. English version of clinical practice guidelines for the management of atopic dermatitis 2024. J Dermatol. 2025;52(2):e70\u2013e142.","DOI":"10.1111\/1346-8138.17544"},{"key":"3536_CR19","unstructured":"Dermavant announces approval of tapinarof in both psoriasis and atopic dermatitis in Japan [press release]. dermavant.com: dermavant2024."},{"issue":"5","key":"3536_CR20","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1001\/jamadermatol.2023.0391","volume":"159","author":"AS Paller","year":"2023","unstructured":"Paller AS, Ladizinski B, Mendes-Bastos P, et al. Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: analysis of the measure up 1, measure up 2, and AD up randomized clinical trials. JAMA Dermatol. 2023;159(5):526\u201335.","journal-title":"JAMA Dermatol"},{"key":"3536_CR21","unstructured":"Ohya Y, Saeki H, Yoshihara S, Narita M. Japanese guidance for the prevention and treatment of pediatric atopic dermatitis. Japanese Society of Pediatric Dermatology, Japan Pediatric Allergy Society. 2024;1(1):11."},{"key":"3536_CR22","unstructured":"Lilly. Updates on OLUMIANT\u00ae (baricitinib) Phase\u00a03 lupus program and FDA review for atopic dermatitis 2022. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/updates-olumiantr-baricitinib-phase-3-lupus-program-and-fda. Accessed 5 Dec 2023."},{"key":"3536_CR23","unstructured":"NICE. Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis 2022. https:\/\/www.nice.org.uk\/guidance\/ta814. Accessed 14 Sept 2023."},{"issue":"1","key":"3536_CR24","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/1346-8138.16635","volume":"50","author":"H Saeki","year":"2023","unstructured":"Saeki H, Akiyama M, Abe M, et al. English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis. J Dermatol. 2023;50(1):e1\u201319.","journal-title":"J Dermatol"},{"issue":"1","key":"3536_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/bjd\/ljad096","volume":"189","author":"A Torrelo","year":"2023","unstructured":"Torrelo A, Rewerska B, Galimberti M, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase\u00a0III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol. 2023;189(1):23\u201332.","journal-title":"Br J Dermatol"},{"issue":"5","key":"3536_CR26","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.jaad.2022.01.018","volume":"87","author":"AS Paller","year":"2022","unstructured":"Paller AS, Guttman-Yassky E, Schuttelaar MLA, Irvine AD, Baselga E, Kataoka Y, et al. Disease characteristics, comorbidities, treatment patterns and quality of life impact in children <12\u00a0years old with atopic dermatitis: interim results from the PEDISTAD Real-World Registry. J Am Acad Dermatol. 2022;87(5):1104\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"3536_CR27","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.jaad.2019.07.105","volume":"82","author":"AS Paller","year":"2020","unstructured":"Paller AS, Siegfried EC, Vekeman F, et al. Treatment patterns of pediatric patients with atopic dermatitis: a claims data analysis. J Am Acad Dermatol. 2020;82(3):651\u201360.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"3536_CR28","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/jdv.14891","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657\u201382.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3536_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17256","author":"A Otsuka","year":"2024","unstructured":"Otsuka A, Wang C, Torisu-Itakura H, et al. Patient and family burden in pediatric atopic dermatitis and its treatment pattern in Japan. Int J Dermatol. 2024. https:\/\/doi.org\/10.1111\/ijd.17256.","journal-title":"Int J Dermatol"},{"key":"3536_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.5114\/dr.2016.59132","volume":"2","author":"M Maciejewska-Franczak","year":"2016","unstructured":"Maciejewska-Franczak M, Majak P, Kaczmarek J, Antczak A. Satisfaction with treatment of atopic dermatitis in children. Dermatol Rev. 2016;2:109\u201318.","journal-title":"Dermatol Rev"},{"issue":"5","key":"3536_CR31","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s13555-021-00580-2","volume":"11","author":"P Anderson","year":"2021","unstructured":"Anderson P, Austin J, Lofland JH, Piercy J, Joish VN. Inadequate disease control, treatment dissatisfaction, and quality-of-life impairments among US patients receiving topical therapy for atopic dermatitis. Dermatol Ther (Heidelb). 2021;11(5):1571\u201385.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"3536_CR32","doi-asserted-by":"crossref","unstructured":"Simpson B, Grada A, Knapp Keith\u00a0D, et al. 569 - Impact of therapeutic inertia on patient-reported outcomes in moderate-to-severe atopic dermatitis: a 12-month longitudinal study from the TARGET-DERM AD registry. Br J Dermatol. 2024;190(Supplement_2):ii61\u2013ii2.","DOI":"10.1093\/bjd\/ljad498.064"},{"issue":"Supplement_2","key":"3536_CR33","doi-asserted-by":"publisher","first-page":"ii60","DOI":"10.1093\/bjd\/ljad498.063","volume":"190","author":"LF Eichenfield","year":"2024","unstructured":"Eichenfield LF, Grada A, Knapp KD, Munoz B, Crawford JM, Silverberg JI. 568 - Persistent inadequate disease control and therapeutic inertia in moderate-to-severe atopic dermatitis: a 12-month longitudinal analysis of real-world outcomes from TARGET-DERM registry. Br J Dermatol. 2024;190(Supplement_2):ii60\u20131.","journal-title":"Br J Dermatol"},{"issue":"10","key":"3536_CR34","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1111\/1346-8138.16932","volume":"50","author":"H Saeki","year":"2023","unstructured":"Saeki H, Akiyama M, Abe M, et al. English version of Japanese guidance for biologics in treating atopic dermatitis. J Dermatol. 2023;50(10):e311\u201322.","journal-title":"J Dermatol"},{"issue":"11","key":"3536_CR35","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"3536_CR36","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","volume":"39","author":"P Anderson","year":"2023","unstructured":"Anderson P, Higgins V, Courcy J, et al. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on disease specific programmes. Curr Med Res Opin. 2023;39(12):1707\u201315.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"3536_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme. BMJ Open. 2016;6(8):e010352.","journal-title":"BMJ Open"},{"key":"3536_CR38","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type\u00a02 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371\u201380.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"3536_CR39","unstructured":"European Pharmaceutical Market Research Association (EphMRA). Code of Conduct 2024 [updated September 2024]. https:\/\/www.ephmra.org\/sites\/default\/files\/2024-09\/2024%20EPHMRA%20Code%20of%20Conduct%20Final.pdf. Accessed 31 Oct 2024."},{"key":"3536_CR40","unstructured":"StataCorp. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC; 2019."},{"issue":"2","key":"3536_CR41","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.alit.2025.01.003","volume":"74","author":"H Saeki","year":"2025","unstructured":"Saeki H, Ohya Y, Arakawa H, et al. Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2024. Allergol Int. 2025;74(2):210\u201321.","journal-title":"Allergol Int"},{"issue":"3","key":"3536_CR42","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaad.2024.05.023","volume":"91","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Eichenfield LF, Hebert AA, et al. Tapinarof cream 1% once daily: significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2\u00a0years of age in the pivotal phase\u00a03 ADORING trials. J Am Acad Dermatol. 2024;91(3):457\u201365.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"3536_CR43","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1111\/1346-8138.17451","volume":"51","author":"A Igarashi","year":"2024","unstructured":"Igarashi A, Tsuji G, Fukasawa S, Murata R, Yamane S. Tapinarof cream for the treatment of atopic dermatitis: efficacy and safety results from two Japanese phase\u00a03 trials. J Dermatol. 2024;51(11):1404\u201313.","journal-title":"J Dermatol"},{"issue":"4","key":"3536_CR44","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","volume":"158","author":"EL Simpson","year":"2022","unstructured":"Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials. JAMA Dermatol. 2022;158(4):404\u201313.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"3536_CR45","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","volume":"157","author":"LF Eichenfield","year":"2021","unstructured":"Eichenfield LF, Flohr C, Sidbury R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol. 2021;157(10):1165\u201373.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"3536_CR46","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","volume":"156","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase\u00a03 randomized clinical trial. JAMA Dermatol. 2020;156(1):44\u201356.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"3536_CR47","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/bjd.21630","volume":"187","author":"T Bieber","year":"2022","unstructured":"Bieber T, Reich K, Paul C, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase\u00a0III clinical trial (BREEZE-AD4). Br J Dermatol. 2022;187(3):338\u201352.","journal-title":"Br J Dermatol"},{"issue":"8","key":"3536_CR48","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/09546634.2019.1623860","volume":"31","author":"Y Okubo","year":"2020","unstructured":"Okubo Y, Ho K-A, Fifer S, Fujita H, Oki Y, Taguchi Y. Patient and physician preferences for atopic dermatitis injection treatments in Japan. J Dermatolog Treat. 2020;31(8):821\u201330.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"3536_CR49","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s13555-021-00631-8","volume":"11","author":"M Ameen","year":"2021","unstructured":"Ameen M, Meller S, Pinter A, Shear NH, Soria A. Perception and experience of biologic therapy in atopic dermatitis: a qualitative focus group study of physicians and patients in Europe and Canada. Dermatol Ther. 2021;11(6):2159\u201377.","journal-title":"Dermatol Ther"},{"issue":"8","key":"3536_CR50","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s13555-024-01232-x","volume":"14","author":"CY Chu","year":"2024","unstructured":"Chu CY, Chan Y, Wananukul S, et al. Bridging the gap: comparing patient-clinician views on treatment goals and communication in the management of atopic dermatitis within the Asia-Pacific region. Dermatol Ther. 2024;14(8):2195\u2013208.","journal-title":"Dermatol Ther"},{"issue":"2","key":"3536_CR51","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s13555-022-00866-z","volume":"13","author":"C Wang","year":"2023","unstructured":"Wang C, Aranishi T, Reed C, et al. Impact of patient and physician disconnect on satisfaction with treatment for atopic dermatitis in Japan. Dermatol Ther (Heidelb). 2023;13(2):505\u201322.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"3536_CR52","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","volume":"145","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Tha\u00e7i D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877\u201384.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"3536_CR53","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00228-022-03400-4","volume":"78","author":"C Alves","year":"2022","unstructured":"Alves C, Penedones A, Mendes D, Batel Marques F. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis. Eur J Clin Pharmacol. 2022;78(12):1923\u201333.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03536-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03536-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03536-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:15:19Z","timestamp":1782209719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03536-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3536"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03536-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Akio Tanaka has served as a speaker\/consultant and for Maruho, Torii Pharma, Sanofi, Otsuka Pharma, Eli Lilly, Pfizer, and Abbie and has a research grant contract with Maruho. Yumi Kang, Junichi Danjo, Takashi Matsuo, and Hitoe Torisu-Itakura are full-time employees and stakeholders of Eli Lilly and Company. Simran Marwaha, Peter Anderson, and James Piercy are full-time employees of Adelphi Real World, an organization that has a vendor contract with Eli Lilly. Atushi Otsuka has served as a speaker for Novartis, Sanofi, Eli Lilly, AbbVie, Janssen Pharmaceutical K.K. and Maruho.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The survey was performed in full accordance with relevant legislation at the time of data collection. Data collection was undertaken in line with European Pharmaceutical Marketing Research Association guidelines and as such did not require ethics committee approval. The study protocol was reviewed and approved by the Pearl Institutional Review Board (#22-ADRW-142) and deemed to be exempt. Using a checkbox, the patient\u2019s caregiver provided informed consent for use of their anonymized and aggregated data for research and publication in scientific journals. All data were aggregated and de-identified before receipt to prevent patient and physician direct identification. No identifiable protected health information was extracted during the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}